PA5-68332

antibody from Invitrogen Antibodies

Targeting: SLC6A20 IMINO, SIT1, XT3, Xtrp3

Provider product page for PA5-68332

Western blot

Other assay

Antibody data

Antibody Data
Antigen structure
References [1]
Comments [0]
Validations
Western blot [1]
Other assay [3]

Submit

Product number: PA5-68332 - Provider product page
Provider: Invitrogen Antibodies
Product name: SLC6A20 Polyclonal Antibody
Antibody type: Polyclonal
Antigen: Synthetic peptide
Description: Predicted to react with Mouse samples.
Reactivity: Human, Mouse
Host: Rabbit
Isotype: IgG
Vial size: 100 µL
Concentration: 1 mg/mL
Storage: -20°C

SLC6A20 protein structure - PA5-68332 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: 2 Figure Increased expression of the Slc6a20a glycine transporter gene and decreased brain glycine levels in the Pten DeltaC / DeltaC mice A A volcano plot showing DEGs (adjusted P value < 0.1) derived from RNA-Seq results for Pten DeltaC / DeltaC and WT mice (P21). For the calculation of adjusted P value, we have employed the R package DESeq2 where the P -values obtained by the Wald test are corrected for multiple testing using the Benjamini and Hochberg method. ( n = 3 mice for WT and DeltaC). See also Dataset EV1 for the full RNA-Seq results. B GSEA analysis of RNA-Seq results from Pten DeltaC / DeltaC and WT mice (P21). Transcripts ranked by levels of expression (DeltaC/WT ratio) were tested for enrichment in precurated gene sets in the C5 (gene ontology) category. NES, normalized enrichment score; positive and negative enrichments indicate a greater contribution of up- and downregulated genes, respectively, to the enrichments (see also Dataset EV2 for the full GSEA results). C Immunoblot validation of the increase in SLC6A20 protein levels in hippocampal lysates of Pten DeltaC / DeltaC mice (P21). We denoted the antibody as ""SLC6A20"" here, not ""SLC6A20A"", because this antibody was generated using a synthetic peptide sequence (YNEPSNNCQKHAI) that is commonly present in SLC6A20A and SLC6A20B, being a pan-SLC6A20 antibody (Thermo Fisher). ( n = 3 mice for WT and Delta C, * P < 0.05, Student's t -test). The error bars represent SEM. D, E Increased phosphorylation of beta

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: 5 Figure Knockdown of SLC6A20A expression by antisense oligonucleotide increases whole-brain glycine levels and NMDAR function and rescues repetitive climbing in Pten DeltaC / DeltaC mice Schematic representation for the intracerebroventricular (ICV) injection of Slc6a20a antisense oligonucleotide (ASO) into the lateral ventricle (LV) for the reduction of Slc6a20a expression in the whole mouse brain. Slc6a20a -ASO decreases the levels of Slc6a20a mRNAs in the brain of WT and Pten DeltaC / DeltaC mice (P20-32), as shown by qRT-PCR analysis performed 1-2 weeks after injection. ( n = 5 mice for WT-Sal/saline, four for WT-ASO, three for DeltaC-Sal, and three for DeltaC-ASO, * P < 0.05, ** P < 0.01, *** P < 0.001, Student's t -test for each comparison). The error bars represent SEM. Slc6a20a -ASO decreases the levels of SLC6A20 proteins in the brain of WT mice (2-4 months), as shown by immunoblot analysis of whole-brain lysates 6 days after injection. ( n = 4 mice, ** P < 0.01, Student's t -test). The error bars represent SEM. Pten DeltaC / DeltaC mice (2-4 months) treated with Slc6a20a -ASO display partially normalized levels of whole-brain glycine, as shown by the lack of difference between saline-treated WT and ASO-treated Pten DeltaC / DeltaC mice. Note that the glycine levels observed here are ~ 4 times lower than those measured in Fig 3A, which could be attributable to different mouse ages (P21 in Fig 3A vs. 2-4 months in Fig 5D), absence and presence of ASO injection, or lo

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: 6 Figure Slc6a20a -mutant mice show abnormal increases in extracellular glycine levels and NMDAR function Schematic diagram showing the generation of Slc6a20a -mutant mice. The SLC6A20 antibody is denoted by ""Y"" above exon (Ex) 6. Decreased levels of Slc6a20a , but not Slc6a20b , mRNAs in the brain of Slc6a20a +/- (HT) and Slc6a20a -/- (KO) mice (P21-28), as shown by qRT-PCR analysis. ( n = 4, 3, 3 mice for WT, HT, and KO; * P < 0.05, ** P < 0.01, ns, not significant, one-way ANOVA with Bonferroni's test). The error bars represent SEM. Reduced expression of SLC6A20 proteins in the brains of Slc6a20a +/- and Slc6a20a -/- mice (P21 for HT and P24-28 for WT and KO), as indicated by immunoblot analysis of total brain lysates. beta-actin and alpha-tubulin were used as loading controls. ( n = 3 mice for WT, HT, and KO, * P < 0.05, Student's t -test). The error bars represent SEM. Increased extracellular levels of glycine and proline in the brain of Slc6a20a +/- and Slc6a20a -/- mice, as shown by microdialysis analyses. Note that glycine levels are increased in both Slc6a20a +/- and Slc6a20a -/- mice, whereas proline levels are increased only in Slc6a20a -/- mice. (glycine, n = 19 mice for WT, 11 for HT, 8 for KO, ** P < 0.01, Mann-Whitney U -test; proline, n = 15 mice for WT, 11 for HT, 14 for KO, *** P < 0.001, ns, not significant, Mann-Whitney U -test). The error bars represent SEM. Increased NMDA/AMPA ratio at hippocampal SC-CA1 synapses in Slc6a20a +/- mice (P17-20), as indic